The methotrexate nanovesicles were able to downregulate IL-1β and TNF-α by upregulating the release of heme oxygenase-1 (HO-1) in intestinal macrophages and had improved anti-inflammatory properties against DSS-induced IBD compared to a free drug. This evidence concerns the gene HMOX1 and inflammatory bowel disease.